加载中
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
前收盘价
US$118.69
−US$0.78 · -0.65%
盘前
US$119
+US$0.31 · +0.26%
10月12日 6:07 ET
盘中时间采用ET。市场数据可能有所延迟。
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
日内区间
当前US$118.69
52周区间
当前US$118.69
盘中时间采用ET。市场数据可能有所延迟。
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
日内区间
当前US$118.69
52周区间
当前US$118.69
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 13.34亿 USD | 13.61亿 USD | 13.09亿 USD | 11.69亿 USD | 9.93亿 USD |
| 销货成本 | 5.9亿 USD | 5.82亿 USD | 5.97亿 USD | 5.46亿 USD | 4.62亿 USD |
| 毛利 | 7.44亿 USD | 7.79亿 USD | 7.12亿 USD | 6.23亿 USD | 5.31亿 USD |
| 研究与开发 | 5976.6万 USD | 6942.2万 USD | 6303.5万 USD | 5863.1万 USD | 5520.1万 USD |
| 销售、一般及管理费用 | 4.42亿 USD | 4.22亿 USD | 4.21亿 USD | 3.74亿 USD | 3.32亿 USD |
| 营业费用 | 5.02亿 USD | 5.57亿 USD | 5.47亿 USD | 4.67亿 USD | 4.5亿 USD |
| 利息支出 | 2870.4万 USD | 974.6万 USD | 1301.8万 USD | 1463万 USD | 1712.1万 USD |
| 折旧和摊销 | 1.12亿 USD | 1.16亿 USD | 9721.5万 USD | 9330.7万 USD | 9774.7万 USD |
| 营业利润 | 2.41亿 USD | 2.22亿 USD | 1.65亿 USD | 1.56亿 USD | 8075万 USD |
| 净利润 | 9730.8万 USD | 1.68亿 USD | 1.18亿 USD | 1.15亿 USD | 4337.5万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$130.8
上涨空间 10.20%价格历史记录不可用
最高：US$140平均的：US$130.8最低：US$119报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.49亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1.45亿0.19%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB1.08亿0.06%1853亿 USD0.03%US$289.48+0.64%
Vanguard Extended Market ETFVXF5565.87万0.06%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO4798.81万0.35%139.17亿 USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS4214.44万0.12%338.69亿 USD0.31%US$78.35+0.32%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY4075.3万0.16%258.17亿 USD0.23%US$669.87+0.54%
Vanguard Morningstar Small-Cap Value ETFVBR3422.27万0.05%682亿 USD0.05%US$234.43+0.22%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASState Street SPDR S&P MIDCAP 400 ETF TrustMDYVanguard Morningstar Small-Cap Value ETFVBRAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
